Sarepta Therapeutics to Present at the 22nd International Annual Congress of the World Muscle Society
September 28, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer
September 25, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day
September 06, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053)
September 06, 2017 07:00 ET
|
Sarepta Therapeutics
-- Study achieved statistical significance on all primary and secondary biological endpoints -- -- Results further validate the Company’s exon-skipping platform for the treatment of DMD -- ...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2017 18:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics to Present at Three Upcoming Investor Conferences
August 24, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2017 18:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications
July 27, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock
July 24, 2017 20:00 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces Proposed $250 Million Public Offering of Common Stock
July 24, 2017 07:00 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique...